Plain-English translation of NCT06058078 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called for patients with active lupus nephritis—a serious kidney condition that develops when lupus damages the kidneys. The study will give some patients the medication along with their current standard treatments, while others receive only standard treatment, to see if the cell injections help reduce kidney damage and improve kidney function. Researchers are enrolling about 60 patients to find the safest dose and best results.
Many patients with lupus nephritis don't respond well enough to standard medications like steroids and immunosuppressants, and their kidney damage continues to worsen. This trial exists to see whether this new treatment can help patients who have failed or cannot tolerate current options, potentially offering hope to those with few other choices.
You likely qualify if…
You likely don't qualify if…
The trial has two stages: first, a smaller group will receive increasing doses of the treatment to check safety, then a larger group of about 60 patients will be randomly assigned to receive either the medication at one of two doses plus standard treatment, or standard treatment alone. You'll continue your current lupus medications throughout the study, receive injections as part of the treatment, and have regular blood and urine tests, kidney function assessments, and follow-up visits to monitor how well the treatment is working and track any side effects for at least a year.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
China